Juno Therapeutics Gmbh

Editas Medicine, Inc.

David Jeffrey Huss

Stephen Jacob Goldfless

Cameron Brandt

Brian J Belmont

Alexandra Croft

Blythe D Sather

Yue Jiang

Timothy G Johnstone

James Sissons

Haley Peper

Gordon Grant Welstead

Dean Y Toy

Stephen Michael Burleigh

Christopher Heath Nye

David Koppstein

Hieu Nguyen

Sonia Timberlake

Queenie Vong

Christopher Borges

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

HPV-specific binding molecules

Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.

T cell receptors and engineered cells expressing same

Growing community of inventors

Seattle, WA, United States of America

David Jeffrey Huss